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Abstract: 22 
Background: 23 
Pain in the anterior and lateral parts of the knee during exercise is a common clinical problem for 24 
which current management strategies are often unsuccessful.  25 
Objective: 26 
To investigate the effect of an ultrasound-guided Botulinum Toxin (BT) injection into tensor fascia 27 
lata (TFL) followed by physiotherapy in patients classified with lateral patellofemoral overload 28 
syndrome (LPOS) who failed to respond to conventional treatment.  29 
Study Design: 30 
Case Series 31 
Methods: 32 
Forty-five patients (mean age: 32±9 (mean±SD)) who met inclusion criteria: 1. activity-related 33 
anterolateral knee symptoms, 2. symptoms greater than 3 months, 3. pathology confirmed by 34 
Magnetic Resonance Imaging, and 4. previous failed physiotherapy, underwent an ultrasound-guided 35 
injection of BT into TFL followed by physiotherapy. Patient reported outcomes were collected at five 36 
time intervals (pre-injection and 1, 4, 12 weeks and a mean 5 years post-injection). In 42 patients, 37 
relative ITB length changes were assessed using modified Ober’s test at the first four time points. A 38 
computational model was run to simulate the effect of TFL weakening on gluteus medius (GMed) 39 
activity. Statistical analysis was undertaken using a one-way ANOVA, and paired t-tests with 40 
Bonferroni post hoc correction. 41 
Results: 42 
There was a significant improvement in AKPS scores from pre-injection (61±15) to 1 (67±15), 4 43 
(70±16), 12 weeks (76±16) and in 87% of patients (39/45 patients available to follow-up) at 44 
approximately 5 years from (62±15.4) to (87±12.5) post injection (All: P<0.01). A significant effect 45 
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on modified Ober’s was identified as a result of the intervention with an increase in leg drop found at 46 
1 (3°±5°), 4 (4°±5°) and 12 (7°±6°) weeks post injection compared to pre-injection (All: P<0.01). 47 
Simulating a progressive reduction in TFL strength resulted in corresponding increases in GMed 48 
activity during gait. 49 
Conclusion: 50 
Injection of BT into TFL combined with physiotherapy resulted in a significant improvement of 51 
symptoms in LPOS patients, maintained at 5 years follow-up. This may result from reduced lateral 52 
TFL/ITB tension or to an increase in GMed activity in response to inhibition of TFL.  53 
Clinical Relevance: 54 
Findings support the use of combined BT injection and physiotherapy to successfully treat a newly 55 
defined sub-population of ‘LPOS’ patients. 56 
  57 
What is known about the subject: 58 
Patellofemoral pain (PFP) and iliotibial band syndrome are known to affect a large number of the 59 
young and active population. However current treatments are commonly unsuccessful in managing 60 
these conditions. The challenge of classifying these patients is recognised with terms including; 61 
‘patellofemoral pain’, ‘anterior knee pain’ and ‘chondromalacia patellae’ commonly used to define 62 
the population. However the symptoms of these patients may vary widely and there is a recognised 63 
need to better define sub-populations of these patients. Ongoing symptoms have previously been 64 
reported in 80% of these patients at 5 years follow up. A prior study successfully treated a similar 65 
patient population, at up to 6 months follow-up, using an injection of BT into vastus lateralis.  66 
 67 
What this study adds to existing knowledge: 68 
Firstly this study defines a sub-population of patients who suffer activity-related anterolateral knee 69 
pain: we have termed this lateral patellofemoral overload syndrome (LPOS) and describe the features 70 
of this clinical presentation clearly. It is also the first study to present findings of BT injection into 71 
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TFL to treat this population, providing rationale for the potential beneficial effects of this 72 
intervention. We hypothesize these may occur as a result of TFL/ITB relaxation and/or increased 73 
gluteal recruitment. Furthermore the data includes long term follow up of results for over 5 years, 74 
which is valuable and rare in this patient population, given the chronicity of the condition, high 75 
activity levels, young age and frequent change of address. 76 
 77 
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Introduction 100 
Superolateral fat pad (SLFP) impingement is known to occur at the lateral aspect of the patellofemoral 101 
joint (PFJ) and can trigger inflammation, causing subsequent fibrous hyperplasia and pain in the 102 
anterolateral region of the knee
16, 17
. Iliotibial band syndrome (ITBS) meanwhile is typified by pain 103 
around the lateral knee during activity
33, 41
, widely thought to result from compression of the fat layer 104 
between the iliotibial band (ITB) and lateral femoral condyle
18
. These pathologies are amongst some 105 
of the most frequent causes of knee pain seen by clinicians
14, 46
, for which conventional interventions 106 
currently include: physiotherapy, orthotics, cortisone injections and surgery (commonly arthroscopy 107 
or lateral release). However such treatments often fail to deliver satisfactory results, particularly in the 108 
longer term
3, 8, 30, 49
. Indeed at five years follow up, 80% of patients have reported ongoing symptoms, 109 
with 74% experiencing reduced activity levels
10
. Hence, there is a clear need for alternative 110 
interventions to help manage this complex patient group with longevity.  111 
 112 
Investigations into these pathologies have primarily focussed on biomechanical differences between 113 
asymptomatic and symptomatic individuals including proximal (e.g. hip abductor weakness)
21
 and 114 
distal factors (e.g. increased navicular drop)
37
. There is evidence suggesting that individuals with pain 115 
display excessive hip adduction and knee internal rotation during running
20, 34, 39
, although, likely 116 
owing to limitations of measurement techniques and differences in participant demographics, these 117 
findings are not consistent
5, 24
. The most common reason attributed to these undesirable kinematic 118 
differences is a lack of gluteal activation
38
 or strength
21, 32, 42
: a hypothesis supported by findings of 119 
improved symptoms in these patients following hip abductor/gluteal strengthening programmes
15, 21
. 120 
Clinically, patients with weak gluteus medius (GMed) may compensate for weakness or inhibition by 121 
substituting with tensor fascia lata (TFL) recruitment. This dysfunctional firing pattern, which may be 122 
a source of chronic TFL tightness, is often identified in anterolateral knee pain patients
22
 although 123 
there is limited evidence to directly support this hypothesis at present.  124 
 125 
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The role of the iliotibial band (ITB) in this patient group has been widely examined. A modified 126 
Ober’s test is commonly used to provide an indirect measure of ITB length, with high intra-rater ICC 127 
(=0.91) values reported
43
. Using this test, it has been shown that ITBS patients have significantly 128 
tighter ITBs than pain-free controls
26, 36
. Anatomically the ITB provides an insertion for the TFL and 129 
gluteus maximus (GMax) muscles proximally, with attachments to the femur, tibia and patella 130 
distally; it has an important role as a knee stabiliser and can influence patellar behaviour via its direct 131 
attachments
29, 35
. Increased ITB tension during cadaveric testing was found to induce lateral patellar 132 
tilt and translation
35
. Furthermore, shorter ITB length has been significantly correlated with lateral 133 
displacement of the patella
25
, whilst patellar lateralisation during hip adduction was significantly 134 
greater in patients with tight ITBs
28
. Elongation of the ITB / TFL complex is recognised to come 135 
primarily from the muscular component given the stiffness of ITB tissue: this could be via improved 136 
TFL flexibility or reduced recruitment
2, 19
. Clinically, physiotherapy directed solely at strengthening 137 
hip musculature and stretching the ITB was 93% successful in these patients; compared to 0% success 138 
in the absence of these factors
47
. This provides a strong case for the need to address TFL/ITB issues in 139 
this population. It is the authors’ belief that these patients should be isolated from other patients with 140 
patellofemoral pain (PFP) and be selected for specific treatment based on their symptoms. In the 141 
present study a population of patients who suffer from Lateral Patellar Overload Syndrome (LPOS) 142 
are therefore defined. These are patients with activity-related symptoms, presenting with either one or 143 
a combination of superolateral fat pad impingement (SLFPI) and ITBS symptoms, identifiable on 144 
Magnetic Resonance Imaging (MRI). Critically the scans should be performed when patients are 145 
symptomatic (i.e. following a provocative activity such as running). Figure 1 shows MRI scans 146 
collected from the same athlete: a. following a period of rest and b. having run to provoke painful 147 
symptoms prior to the scan. Figure 2 shows both SLFPI and ITBS symptoms present on a scan, 148 
supporting the hypothesis that these conditions are not separate entities but are different 149 
manifestations of LPOS.  150 
 151 
Recently, intra musculature injection of botulinum toxin type A (Dysport™) has been used 152 
successfully to reduce vastus lateralis (VL) activity and pain in a more general population of PFP 153 
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patients
45
. Botulinum toxin (BT) produces inhibition of pre-synaptic acetylcholine release, causing a 154 
temporary (approx. 3 month) dose-dependent muscle inhibition
44
. The present study investigates the 155 
short and long term effects of inducing temporary paralysis of TFL using a sonographically-guided 156 
injection of BT combined with a physiotherapy programme aimed at flexibility and strength: the 157 
measured outcomes were ITB length and patient reported outcome scores. Based on prior work it was 158 
hypothesised that BT injected to TFL would cause inhibition resulting in lengthening of the TFL/ITB 159 
complex and necessitating increased GMed recruitment, resulting in a reduction in symptoms. A 160 
cohort of patients displaying symptoms and signs of LPOS were the targeted population. 161 
Computational analysis based on an existing database was also undertaken to investigate the 162 
hypothesis that a reduction in TFL strength would result in increased GMed activity during gait. 163 
 164 
Materials and Methods 165 
Subjects and Study Design 166 
Female and male patients aged between 20 and 50 attending specialised surgeon-led sports medicine 167 
clinics of the lead surgeon, were potential participants in the study. LPOS patients were selected based 168 
on history, clinical examination, special clinical tests (performed by the same experienced orthopaedic 169 
surgeon) and MRI. Patients were considered if they met all of the following inclusion criteria: 1. pain 170 
localised to the anterolateral aspect of the knee (lateral femoral condyle, distal and inferolateral to the 171 
patella), 2. activity-related symptoms (i.e. symptoms coming on with activities such as: running, 172 
jumping, ascending / descending stairs), 3. symptoms of greater than 3 month’s duration, 4. pain 173 
could be reproduced by tensioning the ITB using a modified Ober’s test 5. patients had undergone one 174 
or more failed course(s) of physiotherapy (consisting of best practice evidence based physiotherapy 175 
for this patient population, tailored to individual patient needs and including exercises to address 176 
gluteal, lower abdominals, quadriceps strength and flexibility as indicated) of at least six-weeks 177 
duration, and 6. confirmation of pathology (ITBS and / or SLFPI) based on an MRI scan taken 178 
directly following provocative activity. Patients were excluded from participation in the study if they 179 
had any of the following exclusion criteria: 1. patellar instability (subluxation or dislocation), 2. 180 
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patellar tendinopathy or 3. advanced patellofemoral osteoarthritis. The same experienced orthopaedic 181 
consultant reviewed all patient MRI scans to confirm the presence of SLFPI and / or ITBS. Study 182 
approval was obtained from the committee of Imperial College London.  183 
 184 
Procedures 185 
Patients received an ultrasound-guided injection of 75u of botulinum toxin type A (Dysport™, Ipsen) 186 
in 0.75ml of normal saline into the centre of the TFL muscle belly by an experienced musculoskeletal 187 
radiologist. Patients then underwent assessment and rehabilitation with an experienced 188 
physiotherapist. This consisted of a minimal 6 week course of physiotherapy, with prescribed exercise 189 
volume and subsequent progression determined according to the number an individual could perform 190 
correctly in a session, with patients seen for an average of 5 sessions. Rehabilitation was 191 
individualised to patient needs so a standard pathway was not followed. Patients typically worked on 192 
lower abdominal muscles and pelvic positioning following TFL inhibition. Gluteal exercises in a non-193 
weight bearing and then weight bearing position were taught, single leg strength and control work was 194 
performed, alongside quadriceps strengthening and flexibility exercises as appropriate. Patients ran 195 
when symptom free and when the treating therapist was satisfied that gluteal strength was equal 196 
bilaterally and they had satisfactory single leg control. All these exercises, following a similar 197 
protocol and in line with patient needs, were performed during pre-injection physiotherapy as well.  198 
 199 
Outcome Measures  200 
Patient Reported Outcomes 201 
The primary outcome measure was a change in self-reported knee pain using the Anterior Knee Pain 202 
Scale (AKPS; Kujala Score) before and after treatment
31
. This is a 13 item self-report knee-specific 203 
questionnaire, with a maximum score of 100. Lower marks are indicative of greater disability, and the 204 
scale has a reported minimal detectable change (MDC) of 7 points
7
. AKPS data was collected at five 205 
time intervals: pre-injection and then 1, 4, 12 weeks and a mean 5 years (5.6±1.1; mean±SD) 206 
following the intervention. At 5 years follow-up patients were also asked a further series of questions 207 
as shown in Table 1. 208 
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Modified Ober’s Test 209 
The length of the ITB was measured using a modified Ober’s test, a commonly used test with high 210 
intra-rater ICC (=0.91) values
43
. A MDC of 3.8° for this procedure is reported
40
. Patients were placed 211 
in side lying with the examiner stood behind them, supporting the subjects’ back and pelvis to prevent 212 
unwanted rotation during the test procedure. Patients flexed their lower leg fully and held onto it to 213 
stabilise the position (Figure 3). Their upper knee was then flexed to 90°, and upper hip flexed, 214 
abducted and then extended before the hip was progressively adducted whilst maintaining 90° of knee 215 
flexion until the limit of movement was reached or until unwanted pelvic rotation movements were 216 
induced. A spirit level was placed horizontally at the level of the posterior superior iliac spines (PSIS) 217 
and secured with tape; this was checked to ensure no lateral or anterior-posterior tilting of the pelvis 218 
occurred throughout the measurement procedure. A fluid inclinometer (ISOMED Bi-level 219 
inclinometer) was placed at a standardised position 5cm proximal to the lateral femoral epicondyle. 220 
The ITB length was measured in degrees, with a straight leg in a neutral position being recorded as 0°, 221 
more hip adduction was termed as -°, with less adduction termed as +°. All measurements were 222 
performed by the same experienced examiner. Readings documented from prior time points were not 223 
available for the examiner to view at subsequent follow up, to try to minimize any potential bias. 224 
Measurements were undertaken in 42 patients.  Length changes of the ITB were recorded at four time 225 
intervals: pre-injection and then at 1, 4, and 12 weeks post-injection. 226 
  227 
Computational Modelling 228 
The hypothesis that TFL and GMed muscle activity are related (i.e. a reduction in one will result in an 229 
increase in the other), was investigated by using a well-recognised musculoskeletal model 230 
incorporating 76 muscles
12
 and an example gait dataset for a normal subject
27
, both of which are 231 
freely-available from the OpenSim website
11
. This model calculates the optimum ratio of muscle 232 
forces during gait from the experimentally measured joint kinematic and ground reaction force data 233 
by minimising the sum of the muscle activity squared
13
. First, the model was used to calculate the 234 
muscle forces in the hip abductors (TFL and GMed) for the normal subject during the stance phase of 235 
gait. The effect of a BT injection was then modelled by reducing the TFL’s maximum isometric force 236 
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by 25%, and then by 50% (i.e. the muscle strength was halved). The optimum muscle forces during 237 
single leg stance phase of gait (using the same gait input data) were recalculated for each of these 238 
models and the abductor muscle forces recorded. The effects of a dominant TFL muscle were also 239 
investigated by increasing the muscle’s maximum isometric strength by 25 and 50%, recording the 240 
muscles forces for each case. 241 
 242 
Analysis 243 
Data were analysed in SPSS version 22 (IBM Corp, Armonk, New York). A Shapiro-Wilk test 244 
confirmed that the data sets were normally distributed. A power calculation based on prior AKPS 245 
change scores in a similar population
45
 determined a sample size of 45 necessary to detect a 246 
significant change with 80% power and 95% confidence. To account for drop-outs during the study a 247 
sample of 55 was recruited. 248 
To define the two parts of the study (short term and long term follow-up) two analysis procedures 249 
were undertaken. Initial pre, 1, 4 and 12 week AKPS and ITB data were analysed using a one-way 250 
ANOVA, comparing values obtained from the repeated measurements at different time points. Post-251 
hoc paired t-tests with Bonferroni correction were applied when differences across test conditions 252 
were found. Paired t-tests were then used to compare pre-injection and long term follow up AKPS 253 
scores, from all the patients who were available for follow up at approximately 5 years. Data from 254 
patients who went on to have additional procedures following the initial BT injection were excluded 255 
prior to this analysis (n=7).  256 
 257 
Results 258 
Fifty-five patients were recruited to take part in the study and, accounting for failure to attend follow 259 
up appointments, forty-five patients (32.4±8.6; 17-50 (mean age±SD; range), n=31 females) 260 
completed the study, with 25=right sided knees. It was not possible to collect data on those patients 261 
who did not attend follow up appointments. 262 
 263 
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Patient Reported Short Term Outcomes (12 weeks) 264 
Thirty six out of the forty five patients investigated reported improvement of greater than the MDC, 265 
representing 80% of the study population; the mean improvement from pre-injection to 12 weeks 266 
post-injection was 15±12 (over twice the MDC of the score). Only three patient scores either did not 267 
change (n=2) or worsened (n=1), with a further six patients improving, but less than the MDC 268 
(mean=2.5±1). There was a significant improvement in scores identified from pre-injection (61±15) 269 
compared to one (67±15), four (70±16) and twelve weeks (76±16) post-injection (P<0.001). Post-hoc 270 
tests identified a significant improvement in scores at both four weeks (P=0.02, Mean Difference 271 
(MD)=9.8, 95% CI [1.0-18.6]) and twelve weeks (P<0.001, (MD)=15.4, 95% CI [6.6-24.2]) post 272 
injection compared to pre-injection (Figure 4). 273 
 274 
Modified Ober’s Test 275 
Thirty patients, 71%, had an increase in ITB length greater than the MDC at 12 weeks post-injection. 276 
A significant increase in hip adduction was recorded from pre-injection (2°±9°; mean±SD) compared 277 
to one (-1°±7°), four (-2°±8°) and twelve (-4°±7°) weeks post-injection (P=0.004). There was a 278 
significant difference, interpreted as a lengthening of the ITB, of 6.4°±6 from pre-injection to twelve 279 
weeks post-injection (P=0.002, MD = 6.5, 95% CI [1.8-11.2]) (Figure 5). 280 
 281 
Computational Modelling 282 
The simulated BT injection (decreasing the strength of the TFL by 25 and 50%) resulted in decreased 283 
muscular activity in the TFL, whereas a TFL that was stronger than normal (125% and 150%) served 284 
to incrementally increase its activity (Figure 6).  It was also found that the model required increased 285 
activity in the GMed to compensate for decreased TFL strength and thus maintain the total hip 286 
abduction moment. Conversely the opposite was true when TFL was strengthened; the optimum 287 
balance of muscles forces required decreased GMed activity (Figure 7).   288 
 289 
 290 
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Long-term Follow Up 291 
Thirty nine patients (87%) were able to be contacted at a mean of 5.6±1.1 years (range: 4-6 years) 292 
following injection (Table 1). Four patients went on to have a further 1 or 2 BT injections following 293 
which their symptoms resolved, whilst two patients gained short term effects from the BT and went 294 
on to have a z-lengthening procedure to the distal ITB. A final patient later had a corticosteroid 295 
injection and physiotherapy following the BT injection.  296 
Of the remaining 32 patients, 94% reported the injection helped their symptoms, with the same 297 
patients reporting they would repeat the injection if in the same position. Sixty nine percent of patients 298 
reported no pain in their knee, with the same number having returned to their pre-injury sports level. 299 
Repeat AKPS scores identified a significant improvement from (62.9±15.4) to (87±12.3) post-300 
injection in the 32 patients who only had one BT injection (P<0.01, MD=25, 95% CI [18.7-31.3]). 301 
  302 
Adverse Reactions 303 
Only two patients reported potential adverse responses to the BT injection. One described increased 304 
pain following intervention and the other reported an anxiety attack the day following the injection 305 
which the patient felt could have been related to the injection.  306 
 307 
Discussion 308 
This is the first study to report the successful long-term outcomes of BT injection to TFL combined 309 
with a physiotherapy programme for the treatment of LPOS. Sixty nine percent of patients reported 310 
complete resolution of symptoms at an average of 5 years follow up, far outlasting the expected 311 
duration of the drug. Significant increases in a modified Ober’s test, suggestive of a lengthening of the 312 
TFL / ITB complex, were found in over 70% of patients. In addition the modelling results support the 313 
hypothesis that a reduction in TFL recruitment could instigate increased GMed activation. Although 314 
not measured directly, the findings offer two potential mechanisms for the positive effect of the BT: 315 
an effective lengthening of the ITB/TFL complex or an increased recruitment of GMed to compensate 316 
for the TFL inhibition. The paper also clearly defines what the authors believe to be a sub-population 317 
 
 
13 
 
of patients with anterolateral knee pain secondary to SLFPI and/or ITBS for whom this intervention 318 
offers both more sustained and superior outcomes to those previously reported
49
. 319 
There is presently a growing trend for the use of BT to aid rehabilitation to address muscle 320 
imbalance
9
. A prior study also found success in treating PFP patients with BT
45
, with a similar aim to 321 
the present study; to reduce lateral patellar overload in patients. The patient population had delayed 322 
medial quadriceps activation, which improved with BT injection to the lateral quadriceps with effects 323 
largely sustained at 6-month follow-up. These findings combined with the present study support the 324 
use of BT as an adjunct to physiotherapy in carefully selected patients. There is debate regarding the 325 
existence of delayed VMO activation in this population
6
, with atrophy identified in all portions of the 326 
affected quadriceps in knees of patients with patellofemoral pathology, and no evidence of selective 327 
atrophy of the VMO relative to the VL identified
23
. We believe this raises a question regarding the use 328 
of botox to inhibit VL. We therefore feel that injection into TFL may be preferential to inhibiting a 329 
possibly already weakened VL, but further studies would be required to confirm this. 330 
Long term outcome (>1 year) studies of patients with PFP and ITBS in the literature are very 331 
limited
49
. These results therefore provide valuable data to support the successful non-surgical 332 
management of these patients 5 years following intervention. In this study patients acted as their own 333 
controls, having all failed to improve with physiotherapy highlighting a greater benefit from 334 
combined physiotherapy and BT intervention than physiotherapy alone: at a mean of 5.7 years. A 335 
previous study showed that only 27% of patients were pain-free following physiotherapy alone
3
. The 336 
precise effect of the BT is not clear, however it appears to have either a lengthening effect on the TFL 337 
/ ITB complex or an inhibition of TFL necessitating greater gluteal recruitment, which is known from 338 
prior work to positively impact this population
49
. Indeed it may have an effect on both, with reduced 339 
TFL recruitment resulting in decreased muscle tone and thus an apparent lengthening effect on the 340 
TFL/ITB, with both effecting long-term changes.    341 
The use of BT to manage muscle spasm in TFL has previously been found to reduce symptoms of 342 
persistent TFL tightness in patients following hip arthroplasty
1
. In the present study the hypothesis of 343 
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a lengthening effect of the TFL/ITB complex resulting from the BT injection was supported in over 344 
70% of patients. ITB shortening in this population, as previously discussed
26
, may therefore be a 345 
significant factor in the perpetuation of symptoms. Greater ITB tensioning is known to affect patellar 346 
kinematics
28, 35
, whilst it would also likely result in increased lateral femoral condyle compression, 347 
both potentially contributing to pain in this population
18
. However, the second hypothesis that a 348 
reduction in TFL recruitment increased GMed activation, was not possible to directly support with the 349 
clinical data. Thus we ran a computational model to quantitatively assess how strength changes in the 350 
TFL could affect the optimum recruitment strategy for these primary abductor muscles as they 351 
combine to balance bodyweight and stabilise the hip during single-leg-stance. We identified that with 352 
a progressive reduction in TFL strength there was a corresponding increase in GMed activity and vice 353 
versa. This quantitatively shows that for the same movement, there is flexibility in muscle 354 
recruitment: the amount of activity in the TFL could vary depending on a patient’s muscular strength 355 
and recruitment strategy, something also identified in a dedicated modelling paper
48
. LPOS patients 356 
are known to possess a lack of gluteal activation
38
/strength
21, 32, 42
, however it can be challenging for 357 
clinicians to teach these patients to recruit their gluteal muscles since they are adapted to compensate. 358 
A potential mechanism for the BT effect may therefore be that it forced patients to recruit their gluteal 359 
musculature, since they were no longer able to recruit their TFL, which has been recognised as a 360 
compensation strategy in this population
22
. Thus BT could be used as an adjunct to physiotherapy to 361 
improve outcomes. However, further clinical investigations are necessary to confirm these findings. 362 
Study limitations include the specific inclusion / exclusion criteria, which mean that this sample is not 363 
broadly representative of all patients with PFP or ITBS. However, this is also an advantage since it is 364 
the first time this specific sub-population of patients has been defined in the literature, with a 365 
successful management strategy defined
49
. A greater number of female compared to male subjects 366 
were examined; PFP is thought to more commonly affect females, so this may be representative
4
. 367 
Initial recruitment and diagnosis are important to standardise and therefore all patients were examined 368 
and enrolled by the same orthopaedic surgeon, but this could be a limitation. Physiotherapy 369 
administered was in line with best practice guidelines to manage strength and flexibility issues 370 
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identified by experienced physiotherapists treating these patients. However, precise exercise / dosage 371 
was not standardised; rather it was dependent on patient requirements / ability. This could be seen as 372 
an advantage since the non-standardised protocol means that the only common factor across all 373 
patients was the injection. The computational data was based on kinematic and kinetic data gathered 374 
from a bank stored in OpenSim and was not specific to LPOS patients. Therefore, this data has only 375 
been used to support the study hypothesis rather than for formal analysis. Furthermore we have no 376 
current understanding of the proportion of inhibition resulting from the BT injection to TFL, nor is it 377 
clear if LPOS patients have an overly-developed TFL, although their symptoms suggest hyperactivity 378 
and an over-dependence on the muscle.  Therefore a range of presentations (50%-150%) were 379 
modelled to demonstrate the possible effects of increased/decreased TFL strength. Future studies 380 
could attempt to quantify this and repeat the analysis with data gathered directly from this patient 381 
group to enhance results.  382 
Based on these findings the use of BT into TFL to supplement evidence based physiotherapy 383 
intervention in a clearly defined population of LPOS patients can be supported to reduce pain and 384 
improve function at over 5 years following injection. Although the precise mechanism of this 385 
improvement is not clear, we hypothesize based on our clinical and computational data that this was a 386 
result of a lengthening of the ITB/TFL complex and / or an inhibition of TFL resulting in an increase 387 
in gluteal muscle recruitment. We believe that the latter is the more likely the cause, possibly 388 
effecting a change in motor control which is reason for this to be maintained by patients’ long term. 389 
Both of these mechanisms require further investigation in the clinical setting. Importantly this study 390 
clearly defined a population of patients with anterolateral knee pain, termed Lateral Patellar Overload 391 
Syndrome, which responded to this intervention and BT was not administered to all patients 392 
presenting with PFP, rather a sub-population of these. Botulinum Toxin as an adjunct to 393 
physiotherapy in appropriate populations represents a cost-effective, safe and reversible treatment and 394 
offers an attractive alternative in the management of this challenging patient group who often have 395 
unpredictable outcomes to surgical intervention.  396 
 397 
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Figure 1: Left image: Coronal fat saturated proton density weighted MRI scan demonstrating mild 536 
inflammation of the soft tissues interposed between the iliotibial band and lateral epicondyle.  Right 537 
image: Coronal fat saturated proton density weighted MRI of the same patient after a 15 minute run. 538 
The scan now demonstrates marked inflammation of the same soft tissues. 539 
Figure 2: Axial fat saturated proton density weighted MRI scan demonstrating inflammation in both 540 
the superolateral infrapatellar fat pad (yellow arrow) and iliotibial band bursa (red arrow).   541 
Figure 3: Position for measuring modified Ober’s test (A): Three-way spirit level taped to the 542 
posterior superior iliac spine in sitting and (B) inclinometer used to measure leg drop changes. 543 
 544 
Figure 4: Mean anterior knee pain scores at four different time points in the study: before and three 545 
points after the injection of BT. *Significantly different from pre-injection (P<0.05). 546 
 547 
Figure 5: Mean hip adduction angle in the modified Ober’s position at four different time points in 548 
the study: before and three points after the injection of BT. *Significantly different from pre-injection 549 
(P<0.05). 550 
Figure 6: Muscle force of the TFL muscle (normalised to subject body weight), and its values once it 551 
has been strengthened to 150% and weakened to 50%, during the single leg stance phase of gait: 18%-552 
51%.  553 
Figure 7: Muscle force of the GMed muscle (normalised to subject body weight), and its values 554 
when the TFL has been strengthened to 150% and weakened to 50%, during the single leg stance 555 
phase of gait: 18%-51%. 556 
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Table 1: Responses of patients to follow up questions asked after mean 5 years following BT 571 
injection. 572 
Long-term (5.6±1.1 years) follow up telephone questions Yes No 
Did you suffer from any adverse effects as a result of receiving the BT 
injection (n=39)? 
2 37 
Have you had any other treatment for your knee pain since the injection 
(n=39)? 
7 32 
Do you still have pain in your knee (n=32)? 10 22 
Did the BT injection help with your knee symptoms (n=32)? 30 2 
Would you have the BT injection again if you were in the same situation 
(n=32)? 
30 2 
Did you return to your pre-injury activity level (n=32)? 22 10 
 573 
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